(AWH) Aspira Womens Health - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04537Y1091
AWH: Ovarian, Endometriosis, Diagnostic, Tests, Biomarkers
Aspira Womens Health Inc. (NASDAQ:AWH) specializes in developing noninvasive, AI-powered diagnostic tests for gynecologic diseases, focusing on ovarian cancer and endometriosis. Their tests, such as Ova1Plus, Overa, and OvaWatch, aim to reduce the need for invasive procedures, enhancing patient comfort and outcomes. The company operates Aspira Labs and has partnerships with institutions like Harvard and Quest Diagnostics, leveraging their expertise in biomarker technology.
Technically, AWHs stock is trading below its SMA20 ($0.21) and SMA50 ($0.40), indicating a potential downtrend. Support may be found near $0.15, with resistance at $0.25. The Average True Range (ATR) of $0.06 suggests moderate volatility, leading to possible price swings in the near term.
Fundamentally, AWH is a micro-cap company with a market cap of $3.27M, reflecting its high-risk, high-reward profile. The absence of profitability is concerning, yet their strategic partnerships and focus on innovative diagnostics position them for potential growth. Investors should monitor the companys R&D progress and financial health closely.
Additional Sources for AWH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AWH Stock Overview
| Market Cap in USD | 3m |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| GiC Sub-Industry | Health Care Supplies |
| IPO / Inception | 1996-06-27 |
AWH Stock Ratings
| Growth 5y | -97.7% |
| Fundamental | 8.31% |
| Dividend | 0.0% |
| Rel. Strength Industry | -96.2 |
| Analysts | 5/5 |
| Fair Price Momentum | 0.08 USD |
| Fair Price DCF | - |
AWH Dividends
No Dividends PaidAWH Growth Ratios
| Growth Correlation 3m | -97.2% |
| Growth Correlation 12m | -97.6% |
| Growth Correlation 5y | -92.3% |
| CAGR 5y | -58.24% |
| CAGR/Max DD 5y | -0.58 |
| Sharpe Ratio 12m | -1.45 |
| Alpha | -97.14 |
| Beta | -0.50 |
| Volatility | 195.04% |
| Current Volume | 13302.8k |
| Average Volume 20d | 394.4k |
As of March 16, 2025, the stock is trading at USD 0.14 with a total of 13,302,840 shares traded.
Over the past week, the price has changed by -24.32%, over one month by -40.68%, over three months by -81.33% and over the past year by -96.20%.
Neither. Based on ValueRay Fundamental Analyses, Aspira Womens Health is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 8.31 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AWH as of March 2025 is 0.08. This means that AWH is currently overvalued and has a potential downside of -42.86%.
Aspira Womens Health has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy AWH.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AWH Aspira Womens Health will be worth about 0.1 in March 2026. The stock is currently trading at 0.14. This means that the stock has a potential downside of -35.71%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 5.5 | 3828.6% |
| Analysts Target Price | 5.5 | 3828.6% |
| ValueRay Target Price | 0.1 | -35.7% |